View Financial HealthFarmacosmo 配当と自社株買い配当金 基準チェック /06Farmacosmo現在配当金を支払っていません。主要情報0%配当利回り-3.2%バイバック利回り総株主利回り-3.2%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesNew Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€1.3m net loss in 2 years). Market cap is less than US$100m (€18.2m market cap, or US$21.4m).分析記事 • Jan 06Farmacosmo S.p.A.'s (BIT:COSMO) 35% Share Price Surge Not Quite Adding UpFarmacosmo S.p.A. ( BIT:COSMO ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...Buy Or Sell Opportunity • Jan 05Now 34% overvalued after recent price riseOver the last 90 days, the stock has risen 23% to €0.56. The fair value is estimated to be €0.42, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 0.7% in 2 years. Earnings are forecast to grow by 73% in the next 2 years.分析記事 • Jan 04A Look At The Intrinsic Value Of Farmacosmo S.p.A. (BIT:COSMO)Key Insights Farmacosmo's estimated fair value is €0.42 based on 2 Stage Free Cash Flow to Equity Current share price...お知らせ • Dec 31Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million.Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million on December 30, 2025. A cash consideration of €4 million will be paid by Pet Being. Pet Being will pay an earnout/contingent payment of €1.1 million cash. As part of consideration, €5.1 million is paid towards common equity of Bau Cosmesi. The transaction is subject to approval of offer by target shareholders. illimity Bank S.p.A. acted as financial advisor for Farmacosmo S.p.A. Lovells Studio Legale acted as legal advisor for Farmacosmo S.p.A. Gitti And Partners Studio Legale Associato acted as legal advisor for Pet Being. Italaudit SpA acted as due diligence provider for Pet Being.New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€4.6m). Currently unprofitable and not forecast to become profitable over next 2 years (€1.3m net loss in 2 years). Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (€17.6m market cap, or US$20.7m).お知らせ • Dec 17Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million.Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million on December 15, 2025. A cash consideration of €1.8 million will be paid by Farmacosmo S.p.A. Farmacosmo S.p.A. will pay an earnout/contingent payment of €0.3 million cash. Upon completion, Farmacosmo S.p.A. will own 100% stake in Farmacia De Leo S.R.L. In related transaction Farmacia De Leo Srl sold the physical pharmacy business unit to Nica Sgroi Srl. The effectiveness of the transaction is subject to obtaining authorization for the transfer of the physical pharmacy from the competent authority.Buy Or Sell Opportunity • Oct 20Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to €0.43. The fair value is estimated to be €0.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 85% in the next 2 years.分析記事 • Oct 07Farmacosmo S.p.A.'s (BIT:COSMO) Business Is Trailing The Industry But Its Shares Aren'tIt's not a stretch to say that Farmacosmo S.p.A.'s ( BIT:COSMO ) price-to-sales (or "P/S") ratio of 0.3x seems quite...New Risk • Jul 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€3.1m). Currently unprofitable and not forecast to become profitable over next 3 years (€150k net loss in 3 years). Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€22.9m market cap, or US$27.0m).分析記事 • Jun 28Here's Why Farmacosmo (BIT:COSMO) Can Afford Some DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Price Target Changed • Jun 05Price target decreased by 11% to €1.25Down from €1.40, the current price target is an average from 2 analysts. New target price is 112% above last closing price of €0.59. Stock is down 30% over the past year. The company is forecast to post a net loss per share of €0.04 next year compared to a net loss per share of €0.077 last year.分析記事 • May 23A Look At The Intrinsic Value Of Farmacosmo S.p.A. (BIT:COSMO)Key Insights The projected fair value for Farmacosmo is €0.63 based on 2 Stage Free Cash Flow to Equity Farmacosmo's...お知らせ • Apr 15Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025, at 08:00 W. Europe Standard Time.Reported Earnings • Apr 14Full year 2024 earnings releasedFull year 2024 results: Revenue: €64.3m (down 11% from FY 2023). Net loss: €2.97m (loss narrowed 8.0% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Specialty Retail industry in Italy.分析記事 • Dec 14Revenues Not Telling The Story For Farmacosmo S.p.A. (BIT:COSMO) After Shares Rise 34%Those holding Farmacosmo S.p.A. ( BIT:COSMO ) shares would be relieved that the share price has rebounded 34% in the...New Risk • Nov 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€432k net loss in 2 years). Market cap is less than US$100m (€15.1m market cap, or US$16.0m).分析記事 • Oct 27Farmacosmo S.p.A.'s (BIT:COSMO) Shares Not Telling The Full StoryThere wouldn't be many who think Farmacosmo S.p.A.'s ( BIT:COSMO ) price-to-sales (or "P/S") ratio of 0.4x is worth a...分析記事 • Jul 17Investors Appear Satisfied With Farmacosmo S.p.A.'s (BIT:COSMO) ProspectsThere wouldn't be many who think Farmacosmo S.p.A.'s ( BIT:COSMO ) price-to-sales (or "P/S") ratio of 0.4x is worth a...Price Target Changed • May 02Price target decreased by 21% to €1.40Down from €1.77, the current price target is an average from 2 analysts. New target price is 58% above last closing price of €0.88. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.083 last year.New Risk • May 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€7.0m free cash flow). Earnings have declined by 72% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€1.0m net loss in 3 years). Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€34.3m market cap, or US$36.6m).Major Estimate Revision • Apr 30Consensus revenue estimates decrease by 24%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €97.2m to €73.5m. Specialty Retail industry in Italy expected to see average net income growth of 156% next year. Consensus price target down from €1.77 to €1.66. Share price fell 2.6% to €0.88 over the past week.New Risk • Apr 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.2m market cap, or US$37.7m).New Risk • Jul 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€38.8m market cap, or US$42.9m).Board Change • Feb 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Director Dorothy Rubeis was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 04Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi on February 3, 2023.お知らせ • Jan 10Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 31Farmacosmo S.p.A. has completed an IPO in the amount of €22.999905 million.Farmacosmo S.p.A. has completed an IPO in the amount of €22.999905 million. Security Name: Shares Security Type: Common Stock Securities Offered: 10,222,180 Price\Range: €2.25決済の安定と成長配当データの取得安定した配当: COSMOの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: COSMOの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Farmacosmo 配当利回り対市場COSMO 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (COSMO)0%市場下位25% (IT)1.7%市場トップ25% (IT)4.6%業界平均 (Specialty Retail)3.5%アナリスト予想 (COSMO) (最長3年)n/a注目すべき配当: COSMOは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: COSMOは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: COSMO Italian市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: COSMOが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YIT 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 05:02終値2026/05/20 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Farmacosmo S.p.A. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Mattia PetraccaIntegrae SPAFilippo MazzoleniValueTrack
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€1.3m net loss in 2 years). Market cap is less than US$100m (€18.2m market cap, or US$21.4m).
分析記事 • Jan 06Farmacosmo S.p.A.'s (BIT:COSMO) 35% Share Price Surge Not Quite Adding UpFarmacosmo S.p.A. ( BIT:COSMO ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...
Buy Or Sell Opportunity • Jan 05Now 34% overvalued after recent price riseOver the last 90 days, the stock has risen 23% to €0.56. The fair value is estimated to be €0.42, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 0.7% in 2 years. Earnings are forecast to grow by 73% in the next 2 years.
分析記事 • Jan 04A Look At The Intrinsic Value Of Farmacosmo S.p.A. (BIT:COSMO)Key Insights Farmacosmo's estimated fair value is €0.42 based on 2 Stage Free Cash Flow to Equity Current share price...
お知らせ • Dec 31Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million.Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million on December 30, 2025. A cash consideration of €4 million will be paid by Pet Being. Pet Being will pay an earnout/contingent payment of €1.1 million cash. As part of consideration, €5.1 million is paid towards common equity of Bau Cosmesi. The transaction is subject to approval of offer by target shareholders. illimity Bank S.p.A. acted as financial advisor for Farmacosmo S.p.A. Lovells Studio Legale acted as legal advisor for Farmacosmo S.p.A. Gitti And Partners Studio Legale Associato acted as legal advisor for Pet Being. Italaudit SpA acted as due diligence provider for Pet Being.
New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€4.6m). Currently unprofitable and not forecast to become profitable over next 2 years (€1.3m net loss in 2 years). Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (€17.6m market cap, or US$20.7m).
お知らせ • Dec 17Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million.Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million on December 15, 2025. A cash consideration of €1.8 million will be paid by Farmacosmo S.p.A. Farmacosmo S.p.A. will pay an earnout/contingent payment of €0.3 million cash. Upon completion, Farmacosmo S.p.A. will own 100% stake in Farmacia De Leo S.R.L. In related transaction Farmacia De Leo Srl sold the physical pharmacy business unit to Nica Sgroi Srl. The effectiveness of the transaction is subject to obtaining authorization for the transfer of the physical pharmacy from the competent authority.
Buy Or Sell Opportunity • Oct 20Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to €0.43. The fair value is estimated to be €0.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 85% in the next 2 years.
分析記事 • Oct 07Farmacosmo S.p.A.'s (BIT:COSMO) Business Is Trailing The Industry But Its Shares Aren'tIt's not a stretch to say that Farmacosmo S.p.A.'s ( BIT:COSMO ) price-to-sales (or "P/S") ratio of 0.3x seems quite...
New Risk • Jul 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€3.1m). Currently unprofitable and not forecast to become profitable over next 3 years (€150k net loss in 3 years). Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€22.9m market cap, or US$27.0m).
分析記事 • Jun 28Here's Why Farmacosmo (BIT:COSMO) Can Afford Some DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Price Target Changed • Jun 05Price target decreased by 11% to €1.25Down from €1.40, the current price target is an average from 2 analysts. New target price is 112% above last closing price of €0.59. Stock is down 30% over the past year. The company is forecast to post a net loss per share of €0.04 next year compared to a net loss per share of €0.077 last year.
分析記事 • May 23A Look At The Intrinsic Value Of Farmacosmo S.p.A. (BIT:COSMO)Key Insights The projected fair value for Farmacosmo is €0.63 based on 2 Stage Free Cash Flow to Equity Farmacosmo's...
お知らせ • Apr 15Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025, at 08:00 W. Europe Standard Time.
Reported Earnings • Apr 14Full year 2024 earnings releasedFull year 2024 results: Revenue: €64.3m (down 11% from FY 2023). Net loss: €2.97m (loss narrowed 8.0% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Specialty Retail industry in Italy.
分析記事 • Dec 14Revenues Not Telling The Story For Farmacosmo S.p.A. (BIT:COSMO) After Shares Rise 34%Those holding Farmacosmo S.p.A. ( BIT:COSMO ) shares would be relieved that the share price has rebounded 34% in the...
New Risk • Nov 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€432k net loss in 2 years). Market cap is less than US$100m (€15.1m market cap, or US$16.0m).
分析記事 • Oct 27Farmacosmo S.p.A.'s (BIT:COSMO) Shares Not Telling The Full StoryThere wouldn't be many who think Farmacosmo S.p.A.'s ( BIT:COSMO ) price-to-sales (or "P/S") ratio of 0.4x is worth a...
分析記事 • Jul 17Investors Appear Satisfied With Farmacosmo S.p.A.'s (BIT:COSMO) ProspectsThere wouldn't be many who think Farmacosmo S.p.A.'s ( BIT:COSMO ) price-to-sales (or "P/S") ratio of 0.4x is worth a...
Price Target Changed • May 02Price target decreased by 21% to €1.40Down from €1.77, the current price target is an average from 2 analysts. New target price is 58% above last closing price of €0.88. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.083 last year.
New Risk • May 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€7.0m free cash flow). Earnings have declined by 72% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€1.0m net loss in 3 years). Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€34.3m market cap, or US$36.6m).
Major Estimate Revision • Apr 30Consensus revenue estimates decrease by 24%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €97.2m to €73.5m. Specialty Retail industry in Italy expected to see average net income growth of 156% next year. Consensus price target down from €1.77 to €1.66. Share price fell 2.6% to €0.88 over the past week.
New Risk • Apr 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.2m market cap, or US$37.7m).
New Risk • Jul 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€38.8m market cap, or US$42.9m).
Board Change • Feb 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Director Dorothy Rubeis was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 04Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi on February 3, 2023.
お知らせ • Jan 10Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 31Farmacosmo S.p.A. has completed an IPO in the amount of €22.999905 million.Farmacosmo S.p.A. has completed an IPO in the amount of €22.999905 million. Security Name: Shares Security Type: Common Stock Securities Offered: 10,222,180 Price\Range: €2.25